Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 16, 2025
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Matthew R Tonini, Lauren Catherine M Martires, et al.
Molecular Cancer Therapeutics|October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in CancerAntoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Cancer Research|September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient GlioblastomaJulie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Cell Reports|January 10, 2019
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative PhosphorylationYuting Sun, Madhavi Bandi, Timothy Lofton, et al.
Nature Medicine|June 13, 2018
An inhibitor of oxidative phosphorylation exploits cancer vulnerabilityJennifer R Molina, Yuting Sun, Marina Protopopova, et al.
Pageof 2